Cellosaurus logo
expasy logo

Cellosaurus BJAB (CVCL_5711)

[Text version]
Cell line name BJAB
Synonyms BJAb; BJA-B; BJAB-1; BJA-B1; BJA-B-1
Accession CVCL_5711
Resource Identification Initiative To cite this cell line use: BJAB (RRID:CVCL_5711)
Comments Part of: LL-100 blood cancer cell line panel.
Population: African; Kenyan.
Virology: EBV-negative. Even so that the original tumor tissue was infected with the B95-8 strain of EBV.
Doubling time: ~22 hours (PubMed=179629); ~40-60 hours (DSMZ=ACC-757).
Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526).
Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Groin; UBERON=UBERON_0008337.
Cell type: B-cell; CL=CL_0000236.
Sequence variations
HLA typing Source: PubMed=26589293
Class I
HLA-AA*01:01,02:01
HLA-BB*13:02,35:01
HLA-CC*04:01,06:02

Source: CLS=302006
Class I
HLA-AA*01:02:83,02:01:01
HLA-BB*13:02:01,35:01:01
HLA-CC*04:01:01,06:02:01
Class II
HLA-DPDPB1*04:02:01G
HLA-DQDQA1*01:02:01,05:05:01
DQB1*03:01,06:04:01
HLA-DRDRB1*12:01:01,13:02:01

Source: DSMZCellDive=ACC-757
Class I
HLA-AA*02:01:01,02:01:01
HLA-BB*13:02:01,35:01:01
HLA-CC*04:01:01,06:02:01
Class II
HLA-DPDPA1*01:03:01,01:03:01
DPB1*105:01,105:01
HLA-DQDQB1*03:01:01,06:09:01
HLA-DRDRA*01:01:01,01:02:02
DRB1*12:01:01,13:02:01
Disease Burkitt lymphoma (NCIt: C2912)
Burkitt lymphoma (ORDO: Orphanet_543)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_8659 (BBF)CVCL_VD92 (BJAB GFP-CD20)CVCL_VD93 (BJAB GFP-MS4A4A)
CVCL_VD94 (BJAB GFP-MS4A6A)CVCL_VD95 (BJAB GFP-MS4A7)CVCL_VD96 (BJAB GFP-MS4A8B)
CVCL_VE00 (BJAB HA-MS4A4A)CVCL_VE01 (BJAB HA-MS4A8B)CVCL_B6UM (BJAB-B95.8.6)
CVCL_IZ94 (BJAB-K20)CVCL_9876 (BJAB-K3)CVCL_IZ95 (BJAB-K43)
CVCL_9666 (BJAB-K5)CVCL_IZ96 (BJAB-K6)CVCL_IZ97 (BJAB-K88)
CVCL_YY30 (BJAB-L-YFP)CVCL_YY31 (BJAB-YFP)CVCL_VC38 (BJAB/ADR)
CVCL_B6UK (BJAB-HR1K)CVCL_8660 (BREM)CVCL_5758 (GC-BJAB)
CVCL_C5DJ (sfBJAB)CVCL_1G52 (TF228.1.16)
Sex of cell Female
Age at sampling 5Y
Category Cancer cell line
STR profile Source(s): CLS=302006; DSMZ=ACC-757; PubMed=25877200; Technion Genomics Center

Markers:
AmelogeninX
CSF1PO8,10
D2S133821
D3S135816
D5S81812,13
D7S82010,11
D8S117914,15 (CLS=302006; DSMZ=ACC-757; Technion Genomics Center)
15 (PubMed=25877200)
D13S3179,11
D16S5399,11 (DSMZ=ACC-757; PubMed=25877200; Technion Genomics Center)
9,12 (CLS=302006)
D18S5116,21.2 (DSMZ=ACC-757)
16,22 (PubMed=25877200; Technion Genomics Center)
D19S43312,14
D21S1127,28
FGA27 (DSMZ=ACC-757)
27,28 (PubMed=25877200; Technion Genomics Center)
Penta D10,11
Penta E7
TH017
TPOX6,9
vWA14,15 (CLS=302006; DSMZ=ACC-757; Technion Genomics Center)
14,16 (PubMed=25877200)

Run an STR similarity search on this cell line
Web pages https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/b/cell-lines-detail-73.html
Publications

PubMed=4369887; DOI=10.1073/pnas.71.8.3283; PMCID=PMC388669
Klein G., Lindahl T.L., Jondal M., Leibold W., Menezes J., Nilsson K., Sundstrom C.
Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas.
Proc. Natl. Acad. Sci. U.S.A. 71:3283-3286(1974)

PubMed=171663; DOI=10.1073/pnas.72.9.3518; PMCID=PMC433026
Steinitz M., Klein G.
Comparison between growth characteristics of an Epstein-Barr virus (EBV)-genome-negative lymphoma line and its EBV-converted subline in vitro.
Proc. Natl. Acad. Sci. U.S.A. 72:3518-3520(1975)

PubMed=179629
Menezes J., Leibold W., Klein G., Clements G.B.
Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.
Biomedicine 22:276-284(1975)

PubMed=62724; DOI=10.1002/ijc.2910180513
Klein G., Zeuthen J., Terasaki P.I., Billing R.J., Honig R., Jondal M., Westman A., Clements G.B.
Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines.
Int. J. Cancer 18:639-652(1976)

PubMed=175026; DOI=10.1002/ijc.2910170203
Fresen K.-O., zur Hausen H.
Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains.
Int. J. Cancer 17:161-166(1976)

PubMed=6245632; DOI=10.1007/BF01320759
Lui S.W.-L., Ng M.-H.
Glycoproteins and sialyl transferase of human B lymphoblastoid cell lines.
Arch. Virol. 63:31-41(1980)

PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x
Povey S., Jeremiah S., Arthur E., Steel M., Klein G.
Differences in genetic stability between human cell lines from patients with and without lymphoreticular malignancy.
Ann. Hum. Genet. 44:119-133(1980)

PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336
Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd-Kulikowsk H.D., Parsons R.G.
Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.
J. Immunol. 129:1336-1342(1982)

PubMed=6600440; DOI=10.1007/BF02617996
Uittenbogaart C.H., Cantor Y., Fahey J.L.
Growth of human malignant lymphoid cell lines in serum-free medium.
In Vitro 19:67-72(1983)

PubMed=6231253; DOI=10.1002/ijc.2910330407
Ehlin-Henriksson B., Klein G.
Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Int. J. Cancer 33:459-463(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3495441; DOI=10.1002/eji.1830170503
Kanowith-Klein S., Saxon A., Uittenbogaart C.H.
Constitutive production of B cell differentiation factor-like activity by human T and B cell lines.
Eur. J. Immunol. 17:593-598(1987)

PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x; PMCID=PMC452998
Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.
p53 is frequently mutated in Burkitt's lymphoma cell lines.
EMBO J. 10:2879-2887(1991)

PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493
Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R., Magrath I.T.
Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.
FASEB J. 7:951-956(1993)

PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418
Jain V.K., Judde J.-G., Max E.E., Magrath I.T.
Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
J. Immunol. 150:5418-5428(1993)

PubMed=8558920
Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G.
The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Leukemia 10:142-149(1996)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Leuk. Res. 24:255-262(2000)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.
Leuk. Res. 25:275-278(2001)

PubMed=20054396; DOI=10.1038/nature08638; PMCID=PMC2845535
Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. 3rd, Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A., Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M., Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Nature 463:88-92(2010)

PubMed=23292937; DOI=10.1073/pnas.1205299110; PMCID=PMC3557051
Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W.W.-L., Au W.Y., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C.R., Naresh K.N., Evens A.M., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J., Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S., Dunson D.B., Dave S.S.
Genetic heterogeneity of diffuse large B-cell lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013)

PubMed=23257783; DOI=10.1038/leu.2012.367
Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H., Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S., Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
Leukemia 27:1381-1390(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=26787899; DOI=10.1073/pnas.1524677113; PMCID=PMC4747717
Dekker J.D., Park D., Shaffer A.L. 3rd, Kohlhammer H., Deng W., Lee B.-K., Ippolito G.C., Georgiou G., Iyer V.R., Staudt L.M., Tucker H.O.
Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
Proc. Natl. Acad. Sci. U.S.A. 113:E577-E586(2016)

PubMed=29416618; DOI=10.18632/oncotarget.20378; PMCID=PMC5787470
Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C., Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr., Pham L.V.
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Oncotarget 9:346-360(2018)

PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004
Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H., Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Clin. Cancer Res. 24:3967-3980(2018)

PubMed=30165192; DOI=10.1016/j.canlet.2018.08.020
Qu C.-J., Kunkalla K., Vaghefi A., Frederiksen J.K., Liu Y.-D., Chapman J.R., Blonska M., Bernal-Mizrachi L., Alderuccio J.P., Lossos I.S., Landgraf R., Vega-Vazquez F.
Smoothened stabilizes and protects TRAF6 from degradation: a novel non-canonical role of smoothened with implications in lymphoma biology.
Cancer Lett. 436:149-158(2018)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

Cross-references
Cell line collections (Providers) AddexBio; C0003016/4884
CLS; 302006
DSMZ; ACC-757
Cell line databases/resources cancercelllines; CVCL_5711
CGH-DB; 9192-4
DSMZCellDive; ACC-757
Lonza; 107
TOKU-E; 3575
Anatomy/cell type resources BTO; BTO_0001931
Biological sample resources BioSample; SAMN03470800
CRISP screens repositories BioGRID_ORCS_Cell_line; 741
Chemistry resources ChEMBL-Cells; CHEMBL3308492
ChEMBL-Targets; CHEMBL613536
PharmacoDB; BJAB_102_2019
PubChem_Cell_line; CVCL_5711
Encyclopedic resources Wikidata; Q50348210
Experimental variables resources EFO; EFO_0002815
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM33155
GEO; GSM710427
GEO; GSM710443
GEO; GSM1059805
GEO; GSM3150240
Polymorphism and mutation databases Cosmic; 998715
Cosmic; 1019312
Cosmic; 1037700
Cosmic; 1086323
Cosmic; 1127265
Cosmic; 1517659
Cosmic; 1588562
Cosmic; 1945179
IARC_TP53; 699
Progenetix; CVCL_5711
Proteomic databases PRIDE; PXD012087
Sequence databases EGA; EGAS00001000610
Entry history
Entry creation04-Apr-2012
Last entry update19-Dec-2024
Version number44